Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
and relevant clinical information will be reported in the Impressions section of the reporting template, and the S-Modifier should be utilized For each IF, follow up recommendations were developed for actionable scenarios and are described in the summary table. References 1. CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. Lynch, David A. et al. 1, Octover 2015, Radiology, Vol. 277. 2. Selection criteria for lung-cancer screening. Tammemägi MC, Katki HA (...) Recommendations for the Management of Actionable Incidental Findings in the LungCancer Screening Pilot for People at High Risk 525 University Avenue, 5th Floor, Toronto ON, M5G 2L3 Guidelines for the Management of Actionable Incidental Findings in the LungCancer Screening Pilot for People at High Risk Dr. Micheal McInnis, Lead, Radiology Quality Assurance, University Health Network Dr. Heidi Schmidt, Clinical Radiology Lead, LungCancer Screening Pilot for People at High Risk Michelle Ang
% in females, respectively . Non-small cell lungcancer (NSCLC) accounts for 80%–90% of lungcancers, while small cell lungcancer (SCLC) has been decreasing in frequency in many countries over the past two decades . During the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men (...) , while in women, both SCC and adenocarcinoma are still increasing . The World Health Organization (WHO) estimates that lungcancer is the cause of 1.59 million deaths globally per year, with 71% of them caused by smoking. Tobacco smoking remains the main cause of lungcancer and the geographical and temporal patterns of the disease largely reflect tobacco consumption during the previous decades. Both smoking prevention and smoking cessation can lead to a reduction in a large fraction of lung
Osimertinib in Resected EGFR-Mutated Non-Small-Cell LungCancer. Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lungcancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily (...) ) or placebo for 3 years. The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment). The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety.A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group). At 24 months, 90% of the patients with stage II to IIIA disease in the osimertinib group
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell LungCancer. Among patients with non-small-cell lungcancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with MET-dysregulated advanced NSCLC. Patients were (...) assigned to cohorts on the basis of previous lines of therapy and MET status (MET exon 14 skipping mutation or MET amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the cohort assignments.A total of 364 patients
Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for LungCancer Screening Computed Tomography: Development and Validation of a Prediction Model. Lungcancer screening with chest computed tomography (CT) reduces lungcancer death. Centers for Medicare & Medicaid Services (CMS) eligibility criteria for lungcancer screening with CT require detailed smoking information and miss many incident lungcancers. An automated deep-learning approach based on chest radiograph images may (...) identify more smokers at high risk for lungcancer who could benefit from screening with CT.To develop and validate a convolutional neural network (CXR-LC) that predicts long-term incident lungcancer using data commonly available in the electronic medical record (EMR) (chest radiograph, age, sex, and whether currently smoking).Risk prediction study.U.S. lungcancer screening trials.The CXR-LC model was developed in the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial (n = 41 856
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell LungCancer. RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lungcancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary
The Effect of Advances in Lung-Cancer Treatment on Population Mortality. Lungcancer is made up of distinct subtypes, including non-small-cell lungcancer (NSCLC) and small-cell lungcancer (SCLC). Although overall mortality from lungcancer has been declining in the United States, little is known about mortality trends according to cancer subtype at the population level because death certificates do not record subtype information.Using data from Surveillance, Epidemiology, and End Results (...) (SEER) areas, we assessed lung-cancer mortality and linked deaths from lungcancer to incident cases in SEER cancer registries. This allowed us to evaluate population-level mortality trends attributed to specific subtypes (incidence-based mortality). We also evaluated lung-cancer incidence and survival according to cancer subtype, sex, and calendar year. Joinpoint software was used to assess changes in incidence and trends in incidence-based mortality.Mortality from NSCLC decreased even faster than
Alternative RT schedule/Alternative treatment options Level 5 Less than 10 % capacity Individual case discussion Version: 1 Department: NCCP Radiation Oncology Working Group Update date: 05/06/2020 Code: RO_COVID19_12 3 5 Radical Radiotherapy/SABR (Non-metastatic NSCLC & Limited Stage SCLC) Non-Small Cell LungCancer (NSCLC) Stage/clinical scenario Potential selection criteria Treatment recommendations T1-T2 (selected T3), N0, M0 – eligible for SABR Small tumour and slow growing disease (documented slow (...) but eligible for radical radiotherapy Small tumour and slow growing disease (documented slow growth of previous imaging or pure lepidic adenocarcinoma on biopsy & imaging) Delay (taking into account capacity, risk/benefit to patient) or standard T1-T2 (selected T3) N0, M0 – non- eligible for SABR but eligible for radical radiotherapy Large tumour and/or tumour with documented progression on previous serial imaging and/or pathological subtype other than pure lepidic adenocarcinoma Standard Locally advanced
Selpercatinib (Retevmo) - lung and thyroid cancers Drug Approval Package: RETEVMO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RETEVMO Company: Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Application Number: 213246 Approval Date: 05/08/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review
treatment ? any tumour treatment until disease progression and discontinuation of the study medication ? denosumab c Extract of dossier assessment A19-86 Version 1.0 Atezolizumab (small cell lungcancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 11 - Table 7: Characteristics of the intervention – RCT, direct comparison: atezolizumab + carboplatin + etoposide versus placebo + carboplatin + etoposide(multipage table) Study Intervention Comparison a. Treatment could (...) of the best supportive care (BSC) during the maintenance phase. Extract of dossier assessment A19-86 Version 1.0 Atezolizumab (small cell lungcancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 12 - Treatment was performed until disease progression, unacceptable toxicity, start of another tumour therapy, withdrawal of consent or death; administration of atezolizumab could be continued beyond progression at the investigator’s discretion if clinical benefit continued
Lurbinectedin (Zepzelca) - To treat metastatic small cell lungcancer Drug Approval Package: ZEPZELCA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ZEPZELCA Company: Pharma Mar USA, Inc. Application Number: 213702 Approval Date: 06/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF
Capmatinib (Tabrecta) - To treat patients with non small cell lungcancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF